DSIJ Mindshare

Eris enters Dermatology therapy through the acquisition of Oaknet Healthcare for Rs 650 crore
Shreya Chaware
/ Categories: Trending, Mindshare

Eris enters Dermatology therapy through the acquisition of Oaknet Healthcare for Rs 650 crore

“As Oaknet becomes part of the Eris Group, it provides us with a robust growth platform in the areas of Dermatoloy and Cosmetology." asserts Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd.

Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, yesterday announced its acquisition of a 100 per cent stake in Mumbai-based dermatology focused domestic formulations company Oaknet Healthcare Pvt Ltd for a total consideration of Rs 650 crore.

With a revenue base of Rs195 crore in FY22, Oaknet brings a well-established portfolio of leading brands in Dermatology and Women’s Health to the Eris stable. Eris’ Specialty Franchise will get a significant impetus with this acquisition with Eris now present in 87 per cent of the Rs 55,000 crore Chronic Market, with a leading presence in the major Chronic Therapies in the IPM – Cardiology, Oral diabetes care, Insulin, Neuro/CNS and Dermatology. Oaknet has near 100 per cent coverage of approximately 11,000 dermatologists across India with a 60 per cent penetration and has a pan India sales and distribution presence.

Deal Highlights

  • Eris will acquire 100 per cent stake in Oaknet for Rs 650 crore.
  • The acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly owned subsidiary of Eris.
  • The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings.
Previous Article Is Hang Seng index in for a turnaround or is it just a dead cat bounce?
Next Article Top three stocks that witnessed heavy demand from buyers in the pre-opening session today
Print
676 Rate this article:
3.3
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR